Clinical Trial 46853

Garden Grove, CA 92845


This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.

Qualified Participants Must:

• Recurrent MDD diagnosis with a current episode duration of at least 8 weeks and no more than 24 months
• HAM-D17 total score of 23 or higher at screening and Baseline
• Body mass index (BMI) between 18 and 38 kg/m2 (inclusive)

Qualified Participants May Receive:

Monetary compensation for participation.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.